公开(公告)号：US20240108656A1

公开(公告)日：2024-04-04

申请号：US18539876

申请日：2023-12-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Lan Cao ,  Hui-Hsin Chang ,  Jianxin Hu ,  Yu Qian ,  Xi Shi

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K14/54 ,  C07K16/28 ,  C12N5/00 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464411 ,  A61K39/46444 ,  A61P35/02 ,  C07K14/5443 ,  C07K16/2803 ,  C12N5/0018 ,  C12N5/0646 ,  A61K2239/13 ,  A61K2239/28 ,  A61K2239/48

Abstract: The present disclosure provides, among other things, a method for efficiently producing a cell population enriched in Natural Killer cells (NK cells) from induced pluripotent cells.

公开(公告)号：US20240180968A1

公开(公告)日：2024-06-06

申请号：US18494468

申请日：2023-10-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： James Gavin ,  Michael Curley ,  Lan Cao

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464429 ,  A61P35/02 ,  C07K16/2896 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/38 ,  A61K2239/48

Abstract: The present application provides cord blood-derived natural killer (CB-NK) cells engineered to express chimeric receptors that target ADGRE2. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

公开(公告)号：US20240050566A1

公开(公告)日：2024-02-15

申请号：US18361787

申请日：2023-07-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuxia ZHOU ,  Lan Cao ,  Dayong Gao ,  Qiong Xue ,  Jiusong Sun ,  Huang Zhu

IPC: A61K39/00 ,  A01N1/02 ,  C12N5/0783 ,  A61P35/00

CPC classification number: A61K39/4613 ,  A01N1/0284 ,  C12N5/0646 ,  A61K39/4631 ,  A61P35/00 ,  C12N2510/00 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25

Abstract: The present disclosure provides, among other things, a method of cryopreserving and thawing cells that results in the thawed cells having high cellular viability and functionality post-thawing. In some embodiments, a large-scale method of cryopreserving cells is provided, the method comprising: (a) contacting the cells with a cryopreservation medium; (b) cooling the cells to −80° C. at a controlled rate to minimize latent heat of fusion; and (c) storing the cells in liquid nitrogen vapor phase, thereby cryopreserving the immune cells.